東誠藥業(002675.SZ)上半年淨利降29.32%至1.55億元
格隆匯7月27日丨東誠藥業(002675.SZ)披露2021年半年度報吿,報吿期內,公司實現營業收入18.26億元,同比增長10.93%;歸屬於上市公司股東的淨利潤1.55億元,同比下降29.32%,主要原因為報吿期內肝素鈉主營業務成本較2020年同期上升,同時疊加人民幣兑美元升值,導致毛利率下降。
報吿期內,核藥業務板塊銷售收入5.28億元,同比增長31.95%,其中重點產品18F-FDG報吿期內實現營業收入1.90億元,同比增長43%;雲克注射液實現營業收入1.71億元,同比增長32%。
創新研發方面,報吿期內18F-NaF注射液臨牀試驗進展順利,截至6月底,臨牀病例入組數已接近一半;錸[188Re]依替膦酸鹽注射液Ⅱb期臨牀試驗病例入組已接近尾聲;那屈肝素鈣注射液已提交ANDA申請;其他創新研發項目進展正在按照預期計劃進行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.